This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinical value. To a limited extent, also other tumor markers, which might be of importance in the evaluation of patients with prostate cancer are discussed. In serum, PSA exists in a free form or bound to antichymotrypsin. Interestingly, only 10% of PSA secreted from cancer cells seems to exist in a free form, as compared to 30% of PSA secreted from cells in benign prostatic hyperplasia (BPH). PSA seems to be closely, but not absolutely, related to tumor grade and stage. The mean value of PSA in patients with tumors dominated by Gleason grades 3 or below, was 10 ng/ml, compared to 29 ng/ml in those with higher grades. Patients with PSA values of 5...
We analyzed complexed and free prostate-specific antigen (PSA), the free/total PSA and complexed/fre...
Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify progn...
The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the...
This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinic...
In this chapter the use of prostate specific antigen (PSA) as a tumor marker for prostate cancer is ...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
Serum prostate specific antigen (PSA) is elevated beyond the arbitrary cut-off point of 4.0 ng/ml in...
Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, thera...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
This review concentrates mainly on currently available markers for prostate cancer and cannot cover ...
Prostate-specific antigen (PSA) is a glycoprotein pro-duced exclusively by prostatic tissue. PSA’s a...
UNLABELLED: The introduction of total prostate specific antigen (total PSA) testing in blood has rev...
We analyzed complexed and free prostate-specific antigen (PSA), the free/total PSA and complexed/fre...
Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify progn...
The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the...
This chapter mainly deals with biochemical aspects on prostate specific antigen (PSA) and its clinic...
In this chapter the use of prostate specific antigen (PSA) as a tumor marker for prostate cancer is ...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
The incidence of prostate cancer has increased dramatically during the last 10-15 years and it is no...
Serum prostate specific antigen (PSA) is elevated beyond the arbitrary cut-off point of 4.0 ng/ml in...
Tumor markers are being used in the early detection of cancer disease, diagnostics, prognosis, thera...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnos...
Serum prostate markers, in particular prostate-specific antigen (PSA), have truly revolutionised all...
This review concentrates mainly on currently available markers for prostate cancer and cannot cover ...
Prostate-specific antigen (PSA) is a glycoprotein pro-duced exclusively by prostatic tissue. PSA’s a...
UNLABELLED: The introduction of total prostate specific antigen (total PSA) testing in blood has rev...
We analyzed complexed and free prostate-specific antigen (PSA), the free/total PSA and complexed/fre...
Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify progn...
The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the...